The US Food and Drug Administration has granted Elon Musk’s company Neuralink approval to begin human trials on brain chips.
Twitter and SpaceX’s billionaire owner took to social media this week to congratulate Neuralink on the news. The company has been striving for this moment for six years, but the FDA issued some warnings that Neuralink will have to address ongoing concerns, including the safety of the lithium batteries contained within the device.
Already a subscriber? Log in
Subscribe for just $2 a week
Try a month of The Spectator Australia absolutely free and without commitment. Not only that but – if you choose to continue – you’ll pay just $2 a week for your first year.
- Unlimited access to spectator.com.au and app
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in